Directory
>
Peter Ordentlich
Peter Ordentlich
Chief Scientific Officer | Syndax Pharmaceuticals
Lexington, Massachusetts, United States
Peter Ordentlich
Summary
Peter Ordentlich is a seasoned scientific leader currently serving as the Chief Scientific Officer at Syndax Pharmaceuticals, a role he has held since November 2013. With a Ph.D. in Immunology from the University of Pennsylvania, he has built a robust career in the scientific research and development sector, contributing significantly to the field of translational medicine. Prior to his current position, Peter held various roles at Syndax and the Salk Institute, where he honed his expertise in drug development and research methodologies. His career reflects a deep commitment to advancing scientific knowledge and innovation. Peter's experience spans over two decades, showcasing his ability to lead complex research initiatives in both academic and corporate environments. He is known for his strategic vision and collaborative approach, which have been instrumental in driving scientific advancements. Outside of his professional endeavors, Peter is passionate about mentoring the next generation of scientists and fostering a culture of innovation in the pharmaceutical industry.
Peter Ordentlich
Work Experience
Chief Scientific Officer at
Syndax Pharmaceuticals
November 2013 - Present
Vice President, Translational Medicine at
Syndax Pharmaceuticals
October 2005 - November 2013
Scientist at
Salk Institute for Biological Studies
February 2005 - October 2005
Research Scientist II at
X-Ceptor Therapeutics, Inc.
January 2000 - October 2004
Postdoctoral Fellow at
Salk Institute for Biological Studies
September 1997 - December 1999
Peter Ordentlich
Education
University of Pennsylvania, Ph.D.
January 1991 - January 1997
University of Pennsylvania
January 1986 - January 1990
Frequently Asked Questions about Peter Ordentlich
What is Peter Ordentlich email address?
Peter Ordentlich's primary email address is ***********@syndax.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Peter Ordentlich work for?
Peter Ordentlich is a Chief Scientific Officer at Syndax Pharmaceuticals, a company specializing in Commercial physical research.
Where Peter Ordentlich graduated from?
Peter Ordentlich holds a degree in Immunology from University of Pennsylvania.
How can I directly contact Peter Ordentlich?
To contact Peter Ordentlich directly, you can use the email address ***********@syndax.com. Complete contact information is available upon registration with Muraena.
Who is Peter Ordentlich?
Peter Ordentlich is a seasoned scientific leader currently serving as the Chief Scientific Officer at Syndax Pharmaceuticals, a role he has held since November 2013. With a Ph.D. in Immunology from the University of Pennsylvania, he has built a robust career in the scientific research and development sector, contributing significantly to the field of translational medicine. Prior to his current position, Peter held various roles at Syndax and the Salk Institute, where he honed his expertise in drug development and research methodologies. His career reflects a deep commitment to advancing scientific knowledge and innovation. Peter's experience spans over two decades, showcasing his ability to lead complex research initiatives in both academic and corporate environments. He is known for his strategic vision and collaborative approach, which have been instrumental in driving scientific advancements. Outside of his professional endeavors, Peter is passionate about mentoring the next generation of scientists and fostering a culture of innovation in the pharmaceutical industry.
Peter`s contact details
***********@syndax.com
Colleagues
BD Mentor
VP, clinical development
Executive Director, Clinical Sciences, Revumenib Lead
Executive Director, Clinical Data Management
Executive Director, Head of DMPK & Clinical pharmacology
Vice President Regulatory Affairs and QA
Vice President, Investor Relations and Corporate Communications
Vice President Information Technology
VP, CMC
Vice President, Talent and Experience